曲美他嗪对扩张型心肌病心力衰竭患者心功能的疗效观察

目的：观察曲美他嗪治疗扩张型心肌病（DCM）合并心力衰竭的临床价值。方法：100例DCM合并心力衰竭患者随机分为观察组和对照组,对照组给予常规抗心力衰竭治疗,观察组在常规治疗的基础上加用曲美他嗪治疗。观察治疗前和治疗24周后患者心功能分级及左室射血分数（LVEF）、左室舒张末期内径（LVEDD）、每分心排量（CO）的变化。结果：治疗24周后,对照组总有效率为72.00%（36/50）,观察组总有效率为88.00%（44/50）,两者比较差异有统计学意义（P〈0.05）;两组治疗后LVEDD、CO、LVEF均较治疗前显著改善（P〈0.01）,且观察组治疗后上述指标明显优于对照组（P〈0.01或P〈0.05）。结论：曲美他嗪可以安全有效地改善DCM合并心力衰竭患者的心功能,值得临床推广。

Clinical therapeutic effectiveness of trimetazidine on the treatment of patients with dilated cardiomyopathy associated with chronic congestive heart failure

Objective：To explore the clinical therapeutic effectiveness of trimetazidine on the treatment of dilated cardiomyopathy（ DCM） associated with chronic congestive heart failure（CHF）. Methods：100 patients with DCM associated with CHF were randomly divided into control group and observation group. Patients in the control group were given routinely treated. Patients in the observation group were treated with trimetazidine on the basis of the routine treatment. The course of treatment lasted 24 weeks. The grade of cardiac function, left ventricular ejection fraction（LVEF）,left ventricular end diastolic diameter （LVEDD） and cardiac output （CO）were determined before and after 24 weeks after treatment in both groups. Results：After 24 weeks of treatment, the total effective rate in the control group was 72.00% （36/50）, and in the observation group was 88.00% （44/50）, the difference was statistically significant（P0.05）;Both groups the level of LVEDD, CO, LVEF were significantly improved compared with before the treatment（P0.01）, and the index in the observation group were better than the control group（P0.01 or P0.05）. Conclusion：For patients with dilated cardiomyopathy, long-time treatment with trimetazidine in combination with routine therapy can significantly improve the left cardiac function.